Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 109

Sort by

Sort Order Select

Journal Articles

Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study

Brent L. Wood, Meenakshi Devidas, Ryan J. Summers, Zhiguo Chen, Barbara Asselin, Karen R. Rabin, Patrick A. Zweidler-McKay, Naomi J. Winick, Michael J. Borowitz, William L. Carroll, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger, Kimberly P. Dunsmore, David T. Teachey, Stuart S. Winter

Blood (2023) 142 (24): 2069–2078.

https://doi.org/10.1182/blood.2023020678

Published: 2023

Includes: Supplemental data

Journal Articles

Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131

Blood (2023) 142 (Supplement 1): 961.

https://doi.org/10.1182/blood-2023-190495

Published: 2023

Journal Articles

Patients with Down Syndrome and High-Risk B-Acute Lymphoblastic Leukemia Demonstrate Improved Outcomes on a Modified Chemotherapy Regimen: A Report from Children's Oncology Group Study AALL1131

Vilmarie Rodriguez, Meenakshi Devidas, Zhiguo (Bruce) Chen, Andrew J Carroll, Nyla A. Heerema, Michael J. Borowitz, Brent L. Wood, William L. Carroll, Naomi J Winick, Elizabeth A. Raetz, Mignon L. Loh, Michael J. Burke, Wanda L. Salzer, Stephen P. Hunger, Karen R. Rabin

Blood (2023) 142 (Supplement 1): 824.

https://doi.org/10.1182/blood-2023-185368

Published: 2023

Journal Articles

Genomic landscape of Down syndrome–associated acute lymphoblastic leukemia

Blood (2023) 142 (2): 172–184.

https://doi.org/10.1182/blood.2023019765

Published: 2023

Includes: Supplemental data

Journal Articles

The International Consensus Classification of acute leukemias of ambiguous lineage

Olga K. Weinberg, Daniel A. Arber, Hartmut Döhner, Charles G. Mullighan, Etan Orgel, Anna Porwit, Richard M. Stone, Michael J. Borowitz

Blood (2023) 141 (18): 2275–2277.

https://doi.org/10.1182/blood.2022019493

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Blood (2022) 140 (21): 2228–2247.

https://doi.org/10.1182/blood.2022015853

Published: 2022

Includes: Supplemental data

Journal Articles

Final Results of Phase I/II Trial of Mitoxantrone in Combination with Clofarabine (MITCL) in Children with Relapsed/Refractory Acute Leukemia

Jessica C Hochberg, Javier Oesterheld, Aliza Gardenswartz, Liana Klejmont, Jaclyn Basso, Elizabeth Mintzer, Lauren Harrison, Michael J Borowitz, Michael R. Loken, Mitchell S Cairo

Blood (2022) 140 (Supplement 1): 6140–6141.

https://doi.org/10.1182/blood-2022-167040

Published: 2022

Journal Articles

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non- CRLF2 -Rearranged JAK Pathway Alterations

Sarah K Tasian, Deborah S Hunter, I-Ming L Chen, Richard C Harvey, Andrew J. Carroll, Elizabeth Wagner, Shalini C Reshmi, Michael J Borowitz, Brent L. Wood, Jeannie Daniel, Meenakshi Devidas, Elizabeth A. Raetz, Stephen P. Hunger, Albert Assad, Mignon L. Loh

Blood (2022) 140 (Supplement 1): 6117–6118.

https://doi.org/10.1182/blood-2022-164699

Published: 2022

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report

Sumit Gupta, MD, David T. Teachey, MD, Meenakshi Devidas, PhD, Zhiguo Chen, Kimberly P. Dunsmore, MD, Eric C Larsen, MD, Kelly Maloney, MD, Leonard A. Mattano, MD, Stuart S. Winter, MD, Andrew J Carroll, Nyla A Heerema, PhD, Michael J Borowitz, MD PhD, Brent L Wood, MD PhD, William L. Carroll, MD, Naomi J Winick, MD, Elizabeth A. Raetz, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-136609

Published: 2020

Journal Articles

Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-139081

Published: 2020

Journal Articles

Outcomes of Patients with Down Syndrome and CRLF2 -Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-143165

Published: 2020

Journal Articles

Outcomes of Patients with CRLF2 -Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134327

Published: 2020

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Maureen M O'Brien, MD, Lingyun Ji, PhD, Nirali N. Shah, MD, Susan R. Rheingold, MD, Deepa Bhojwani, MD, Joanna S. Yi, MD, Constance M. Yuan, MD PhD, Andrew C Harris, MD, Patrick A. Brown, MD, Michael J. Borowitz, MD PhD, Olga Militano, PharmD, Meenakshi Devidas, PhD, Elizabeth A. Raetz, MD, Lia Gore, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_1): 741.

https://doi.org/10.1182/blood-2019-128977

Published: 2019

Journal Articles

Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932

Anne Angiolillo, MD, Reuven J. Schore, MD, John Kairalla, Meenakshi Devidas, Karen R. Rabin, MD PhD, Patrick A. Zweidler-McKay, MD PhD, Michael J. Borowitz, MD PhD, Brent L Wood, MD PhD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Mary V. Relling, PharmD, Ashley Lane, Kelly Maloney, MD, Cindy Wang, MS, William L. Carroll, MD, Naomi Winick, MD, Elizabeth A. Raetz, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD

Blood (2019) 134 (Supplement_1): 824.

https://doi.org/10.1182/blood-2019-123565

Published: 2019

Journal Articles

Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232

Michael J. Burke, MD, Meenakshi Devidas, PhD, Zhiguo Chen, MS, Wanda Salzer, MD, Elizabeth A. Raetz, MD, Karen R. Rabin, MD PhD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Julie M. Gastier Foster, Michael J. Borowitz, MD PhD, Brent L Wood, MD PhD, Naomi Winick, MD, William Carroll, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD, Eric Larsen, MD

Blood (2019) 134 (Supplement_1): 286.

https://doi.org/10.1182/blood-2019-127052

Published: 2019

Journal Articles

The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia

Kathryn G. Roberts, PhD, Samuel W. Brady, PhD, Zhaohui Gu, PhD, Lei Shi, PhD, Stanley Pounds, PhD, Deqing Pei, MS, Cheng Cheng, PhD, Yunfeng Dai, PhD, Meenakshi Devidas, PhD, Chunxu Qu, PhD, Ashley Hill, BS, Xiaotu Ma, Lei Wei, PhD, Sasi Arunachalam, PhD, Kohei Hagiwara, MD, Yangling Liu, Diane Flasch, Yu Liu, PhD, Matthew Parker, PhD, Xiaolong Chen, PhD, Yongjin Li, PhD, Yiping Fan, PhD, Robert Michael, PhD, Michael Rusch, BS, Mark Wilkinson, Scott Foy, PhD, Dale Hedges, PhD, Scott Newman, PhD, Xin Zhou, PhD, Jian Wang, Shalini C. Reshmi, PhD, Julie M. Gastier-Foster, PhD, Patee Gesuwan, Malcolm A Smith, MD PhD, Daniela S. Gerhard, PhD, Naomi Winick, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Richard C. Harvey, PhD, Cheryl L. Willman, MD, Eric Larsen, MD, Elizabeth A. Raetz, MD, Michael J. Borowitz, MD PhD, Brent L Wood, MD PhD, William L. Carroll, MD, Patrick A. Zweidler-McKay, MD PhD, Karen R. Rabin, MD PhD, Leonard A. Mattano, MD, Kelly Maloney, MD, Stuart S. Winter, MD, Michael J. Burke, MD, Wanda L. Salzer, MD, Kimberly P. Dunsmore, Anne Angiolillo, MD, Kristine R Crews, PharmD, James R. Downing, MD, Sima Jeha, MD, William E. Evans, PharmD, Ching-Hon Pui, MD, Jun J. Yang, PhD, Mary V. Relling, PharmD, Stephen P. Hunger, MD, Mignon L. Loh, MD, Jinghui Zhang, PhD, Charles G. Mullighan, MBBS, MD

Blood (2019) 134 (Supplement_1): 649.

https://doi.org/10.1182/blood-2019-124881

Published: 2019

Journal Articles

FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study

Patrick A. Brown, MD, John Kairalla, Joanne M. Hilden, MD, Zoann Eckert Dreyer, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Cindy Wang, MS, Meenakshi Devidas, PhD, William L. Carroll, MD, Elizabeth A. Raetz, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Michael J. Borowitz, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 1293.

https://doi.org/10.1182/blood-2019-130564

Published: 2019

Journal Articles

Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome

Austin L. Brown, Adam J. de Smith, Vincent U. Gant, Wenjian Yang, Michael E. Scheurer, Kyle M. Walsh, Jonathan M. Chernus, Noah A. Kallsen, Shanna A. Peyton, Gareth E. Davies, Erik A. Ehli, Naomi Winick, Nyla A. Heerema, Andrew J. Carroll, Michael J. Borowitz, Brent L. Wood, William L. Carroll, Elizabeth A. Raetz, Eleanor Feingold, Meenakshi Devidas, Lisa F. Barcellos, Helen M. Hansen, Libby Morimoto, Alice Y. Kang, Ivan Smirnov, Jasmine Healy, Caroline Laverdière, Daniel Sinnett, Jeffrey W. Taub, Jillian M. Birch, Pamela Thompson, Logan G. Spector, Maria S. Pombo-de-Oliveira, Andrew T. DeWan, Charles G. Mullighan, Stephen P. Hunger, Ching-Hon Pui, Mignon L. Loh, Michael E. Zwick, Catherine Metayer, Xiaomei Ma, Beth A. Mueller, Stephanie L. Sherman, Joseph L. Wiemels, Mary V. Relling, Jun J. Yang, Philip J. Lupo, Karen R. Rabin

Blood (2019) 134 (15): 1227–1237.

https://doi.org/10.1182/blood.2018890764

Published: 2019

Includes: Supplemental data

NARROW

Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study

Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131

Patients with Down Syndrome and High-Risk B-Acute Lymphoblastic Leukemia Demonstrate Improved Outcomes on a Modified Chemotherapy Regimen: A Report from Children's Oncology Group Study AALL1131

Genomic landscape of Down syndrome–associated acute lymphoblastic leukemia

The International Consensus Classification of acute leukemias of ambiguous lineage

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Final Results of Phase I/II Trial of Mitoxantrone in Combination with Clofarabine (MITCL) in Children with Relapsed/Refractory Acute Leukemia

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non- CRLF2 -Rearranged JAK Pathway Alterations

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report

Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report

Outcomes of Patients with Down Syndrome and CRLF2 -Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

Outcomes of Patients with CRLF2 -Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932

Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232

The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia

FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study

Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only